Market Research Logo

Pulmonary Arterial Hypertension - Pipeline Review, H2 2015

Pulmonary Arterial Hypertension - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2015’, provides an overview of the Pulmonary Arterial Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pulmonary Arterial Hypertension Overview
Therapeutics Development
Pipeline Products for Pulmonary Arterial Hypertension - Overview
Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis
Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pulmonary Arterial Hypertension - Products under Development by Companies
Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Celsion Corporation
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
Insmed Incorporated
Lacer, S.A.
LTT Bio-Pharma Co., Ltd.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
Peloton Therapeutics, Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Pulmokine, Inc.
Reata Pharmaceuticals, Inc.
Respira Therapeutics, Inc.
Sagene Pharmaceuticals, Inc.
Silence Therapeutics Plc
Sinoxa Pharma GmbH
SteadyMed Therapeutics, Inc.
Suda Ltd
Toray Industries, Inc.
Pulmonary Arterial Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(allopurinol + apocynin) - Drug Profile
Antibody for Cancer and PAH - Drug Profile
Antibody for Pulmonary Arterial Hypertension - Drug Profile
APT-102 - Drug Profile
bardoxolone methyl - Drug Profile
beraprost sodium ER - Drug Profile
beraprost sodium SR - Drug Profile
BIA-51058 - Drug Profile
CT-2009 - Drug Profile
Drugs to Antagonize Notch Receptor 3 for Pulmonary Arterial Hypertension - Drug Profile
fasudil - Drug Profile
GS-4997 - Drug Profile
imatinib mesylate - Drug Profile
INS-1009 - Drug Profile
LA-419 - Drug Profile
lisuride - Drug Profile
MFC-001 - Drug Profile
MFC-002 - Drug Profile
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile
Oligonucleotide to Inhibit miR-145 for PAH - Drug Profile
PB-1046 - Drug Profile
PB-1120 - Drug Profile
Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile
PGC-VIP - Drug Profile
PK-10453 - Drug Profile
PK-10571 - Drug Profile
PLX-PAD - Drug Profile
PT-2977 - Drug Profile
QCC-374 - Drug Profile
R-190 - Drug Profile
ralinepag - Drug Profile
RT-234 - Drug Profile
selegiline + PDE-5 Inhibitor - Drug Profile
selexipag - Drug Profile
Small Molecule for Pulmonary Arterial Hypertension - Drug Profile
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile
SPI-054 - Drug Profile
SPI-183 - Drug Profile
SUD-004 - Drug Profile
tacrolimus - Drug Profile
tadalafil - Drug Profile
tiprelestat - Drug Profile
TPN-171 - Drug Profile
TR-422 - Drug Profile
treprostinil - Drug Profile
treprostinil diolamine - Drug Profile
TXA-127 - Drug Profile
udenafil - Drug Profile
Pulmonary Arterial Hypertension - Recent Pipeline Updates
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2015
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Carolus Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Lacer, S.A., H2 2015
Pulmonary Arterial Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H2 2015
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Sinoxa Pharma GmbH, H2 2015
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2015
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2015
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H2 2015
Pulmonary Arterial Hypertension - Dormant Projects, H2 2015
Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2015
Pulmonary Arterial Hypertension - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2015
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report